Objective:

To investigate how different adjuvants influence the hierarchy of immunodominant B-cell epitopes of FimA and their impact on vaccine efficacy against hypervirulent Klebsiella pneumoniae.

Approach:

Key Findings:

• AddaS03-immunized mice exhibited 100% survival and reduced pulmonary bacterial load.
• AddaVax-immunized mice showed only 40% survival.
• Different adjuvants resulted in varying opsonophagocytic killing activities and inflammatory cytokine levels.
• Three novel immunodominant epitopes were identified, with their hierarchies altered by different adjuvants.
• Immunization with a mixture of FimA immunodominant epitopes plus AlPO4 achieved an 80% protection rate.

Interpretation:

Adjuvants enhance anti-FimA immunity and modulate FimA epitope hierarchies.

Limitations:

• The study was conducted in a murine model, which may not fully replicate human immune responses.
• The long-term efficacy and safety of the vaccine formulations were not assessed.

Conclusion:

Rational adjuvant selection may optimize FimA-induced immune responses in Klebsiella pneumoniae vaccines.

Source

Based on findings from:

Adjuvant-driven epitope hierarchy correlates with the protective efficacy of FimA vaccine against Klebsiella pneumoniae

Guangyang Ming, Longlong Chen, Pengju Yan, Xiaoqiong Wang, Zhifu Chen, Qiang Gou, Yue Yuan, Jiayi Chen, Haiming Jing, Ping Luo, Quanming Zou, Jinyong Zhang, Zhiyong Liu, Renjian Hu, Zhuo Zhao. Frontiers In Immunology, 2026.

https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1796753/full

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.